Difficulty: Medium
Average Score: 80%
Practice
In the context of neonatal respiratory distress syndrome (RDS), which of the following is typically administered?
Correct answer
B
Rationale
In the context of neonatal respiratory distress syndrome (RDS), which is characterized by insufficient surfactant production in premature infants leading to respiratory complications, the typical administration is corticosteroids (Option B). Corticosteroids are given to stimulate surfactant production in the lungs, helping to improve respiratory function and prevent complications associated with RDS.
Antibiotics (Option A) are not typically administered for RDS because it is not an infectious condition. RDS is primarily a result of surfactant deficiency, not a bacterial infection. Bronchodilators (Option C) are not indicated in the treatment of RDS as the primary issue is not bronchoconstriction but rather surfactant deficiency. Oxygen therapy (Option D) is often used in the management of RDS to support oxygenation, but corticosteroids specifically target the underlying cause of surfactant deficiency.
In an educational context, understanding the rationale behind the treatment of neonatal RDS is crucial for nurses and healthcare providers working in neonatal intensive care units. Knowing the appropriate medications and interventions for RDS can help improve patient outcomes and prevent complications associated with respiratory distress in premature infants. It is essential to prioritize treatments that address the underlying pathophysiology of RDS, such as corticosteroids to stimulate surfactant production, to provide optimal care for neonates with this condition.
Antibiotics (Option A) are not typically administered for RDS because it is not an infectious condition. RDS is primarily a result of surfactant deficiency, not a bacterial infection. Bronchodilators (Option C) are not indicated in the treatment of RDS as the primary issue is not bronchoconstriction but rather surfactant deficiency. Oxygen therapy (Option D) is often used in the management of RDS to support oxygenation, but corticosteroids specifically target the underlying cause of surfactant deficiency.
In an educational context, understanding the rationale behind the treatment of neonatal RDS is crucial for nurses and healthcare providers working in neonatal intensive care units. Knowing the appropriate medications and interventions for RDS can help improve patient outcomes and prevent complications associated with respiratory distress in premature infants. It is essential to prioritize treatments that address the underlying pathophysiology of RDS, such as corticosteroids to stimulate surfactant production, to provide optimal care for neonates with this condition.